Edition:
United States

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

8.59USD
23 Feb 2018
Change (% chg)

$0.40 (+4.88%)
Prev Close
$8.19
Open
$8.29
Day's High
$8.65
Day's Low
$8.28
Volume
228,975
Avg. Vol
138,472
52-wk High
$9.69
52-wk Low
$1.89

Select another date:

Wed, Feb 14 2018

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060

* PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING Source text: (http://bit.ly/2oXTLTa) Further company coverage:

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

BRIEF-Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors

* Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors

BRIEF-Pieris Pharmaceuticals reports Q3 loss per share $0.16

* Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update

Select another date: